Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19

Qu, Ye-Min; Kang, Enming; Cong, Haiyan

doi:10.1016/j.tmaid.2020.101619

Cited by 86 publications

(84 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have shown the existence of RP patients [9][10][11][12], however their clinical characterization as not well defined. This study retrospective analyzed the clinical and followed-up data in a cohort of RP and NRP patients in the same discharge period.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test

Liao

Xiao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background It has been reported that several cases recovered from COVID-19 tested positive for SARS-CoV-2 after discharge (re-detectable positive, RP), however the clinical characteristics, significance and potential cause of RP patients remained elusive.Methods A total of 262 COVID-19 patients were discharged from January 23 to February 25, 2020, and were enrolled for analysis of their clinical parameters. The RP and non-RP (NRP) patients were grouped according to the disease severity during their hospitalization period. The clinical characterization at re-admission to the hospital was analyzed. SARS-CoV-2 RNA and plasma antibody levels were detected using high-sensitive detection methods.Findings Up to March 10, 2020, all of patients were followed up for at least 14 days, and 38/262 of RP patients (14.5%) were present. The RP patients were characterized by being less than 14-years old and having mild and moderate conditions as compared to NRP patients, while no severe patients became RP.Retrospectively, the RP patients displayed fewer symptoms, more sustained remission of CT imaging and earlier RNA negative-conversion but similar plasma antibody levels during their hospitalization period as compared to those NRP patients. When re-admitted to the hospital, these RP patients showed no obvious clinical symptoms or disease progression indicated by normal or improving CT imaging and inflammatory cytokine levels. All 21 close contacts of RP patients were tested negative for SARS-CoV-2 RNA, and no suspicious clinical symptoms were reported. However, 18/24 of RNA-negative samples detected by the commercial kit were tested to be positive for virus RNA using a hyper-sensitive method, suggesting the carrier status of virus possibly existed in patients recovered from COVID-19.Interpretation Our results showed that young and mild COVID-19 patients seem to be RP patients after discharge, who show no obviously clinical symptoms and disease progression upon re-admission. More sensitive RNA

show abstract

Section: Discussionmentioning

confidence: 99%

“…Re-detectable positive (RP) of SARS-CoV-2 RNA test in some recovered patients has been reported [9][10][11][12]. The management of RP patients has attracted wide attention.…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test

Liao

Xiao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…There were 3 cases (3/110, 2.7%) whose SARS-CoV-2 RNA was found to be positive again after discharge in our study. Some case reports also suggested this phenomenon [16,17]. Zhou and colleagues suggested some possible reasons to explain this status in their recent review [18]: 1) Virological properties of SARS-CoV-2 were not su ciently understood given that it was just discovered recently; 2) Some host factors, such as the immune function status or coexisting disorders, might in uence the control of the virus in the body; 3) Use of systemic corticosteroids might be related to the recurrence of SARS-CoV-2 RNA; 4) The tests results had been false negative when the patients were discharged; 5)…”

Section: Discussionmentioning

confidence: 88%

Clinical characteristics of Coronavirus Disease 2019 in Hangzhou, China: the combination of lopinavir/ritonavir, interferon, and arbidol may be a well choice for antiviral therapy in common cases

Wang

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Since December 2019, when Coronavirus Disease 2019 (COVID-19) emerged in Wuhan, China, it is currently causing outbreaks in many countries worldwide. No specific therapeutics have yet been proven effective for the treatment of COVID-19. Methods A retrospective, single-center case series study was conducted in a designated hospital for special treatment of COVID-19 in Hangzhou, China. Clinical characteristics of COVID-19 patients were described and compared between the common and severe groups. Multiple linear regression and sensitivity analysis was conducted to evaluate the antiviral effects of the 3-drug combination therapy (lopinavir/ritonavir, interferon, and arbidol). Results One hundred and ten confirmed COVID-19 patients were enrolled, including 99 common cases and 11 severe cases. The mean age was 43.1 years and 54.5% were female. Severe patients might be older (P < 0.01), and have more coexisting disorders (P < 0.01), lower levels of lymphocyte counts (P = 0.016), blood sodium (P = 0.039) and chloride (P < 0.01), and higher levels of C reactive protein and procalcitonin (both P < 0.01). Multiple linear regression and sensitivity analysis indicated that both in Model 1 and Model 2, after adjusted by confounding factors, significant associations between completing the 3-drug combination antiviral therapy (vs. incompleting) and a shorter hospital staying time could be seen (B = -5.970, 95% CI, -9.222, -2.718, P < 0.01, in Model 1; and B = -5.948, 95% CI, -10.622, -1.274, P = 0.014, in Model 2). Conclusions Severe patients might be older and have more comorbidities. The combination of lopinavir/ritonavir, interferon, and arbidol may be a well choice for antiviral therapy, especially in adult common cases.

show abstract

“…Fortunately, the majority of hospitalized COVID-19 patients have been successfully discharged. However, many studies have reported that those discharged from hospital could be tested viral nucleic acid positive again [2][3][4][5], arising the possibility of a potential re-infection.…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics Analysis of the “Re-positive” Discharged COVID-19 Pneumonia Patients in Wuhan, China

Sun

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To analyze the clinical characteristics of the re-positive discharged COVID-19 patients and find markers to distinguish them.Methods：The demographic features, clinical symptoms, laboratory results, comorbidities, co-infections, treatments, illness severities and chest CT scan results of 267 patients were collected during 1st January and 15th February 2020. COVID-19 was diagnosed by RT-PCR. The subsequent clinical symptoms and nucleic acid test results was obtained during the 14 days post-hospitalization quarantine.Results: 30 out of 267 COVID-19 patients were detected re-positive during the post-hospitalization quarantine. Re-positive patients couldn’t be distinguished by demographic features, clinical symptoms, laboratory results, comorbidities, co-infections, treatments, chest CT scan results or subsequent clinical symptoms. However, the re-positive rate were found illness severity correlated, along with APACHE II and CURB-65.Conclusion: Common clinical characteristics arn’t able to distinguish re-positive patients. However, severe and critical cases with high APACHE II and CURB-65 scores are more likely to turn re-positive after discharge.Authors Shengyang He, Wenwu Sun, Kefu Zhou contributed equally to this work.

show abstract

Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19

Cited by 86 publications

References 1 publication

Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test

Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test

Clinical characteristics of Coronavirus Disease 2019 in Hangzhou, China: the combination of lopinavir/ritonavir, interferon, and arbidol may be a well choice for antiviral therapy in common cases

Clinical Characteristics Analysis of the “Re-positive” Discharged COVID-19 Pneumonia Patients in Wuhan, China

Contact Info

Product

Resources

About